Wiman B, Ljungberg B, Chmielewska J, Urdén G, Blombäck M, Johnsson H
J Lab Clin Med. 1985 Feb;105(2):265-70.
Some aspects of the function of the fibrinolytic system have been investigated in 37 patients with a recent incident of symptomatic and confirmed deep vein thrombosis and compared with findings in 20 healthy persons. New specific methods to measure tissue plasminogen activator (t-PA) activity and antigen before and after venous occlusion and the recently discovered fast inhibitor to t-PA were employed. Thirteen of the patients with deep vein thrombosis (35%) had t-PA activity less than 0.5 IU/ml after venous occlusion, whereas the lowest activity found among the healthy individuals was 0.56 IU/ml. The t-PA inhibitor level in the total patient group was 3.8 +/- 3.7 U/ml (range 0 to 15.0 U/ml; median 2.9 U/ml) as compared with 0.7 +/- 0.7 U/ml in the healthy (median 0.5, range 0 to 2.4 U/ml). In the 13 patients with low t-PA activity in postocclusion plasma samples the inhibitor level was 6.0 +/- 4.4 U/ml. Furthermore, in this group of patients a significantly lesser release of t-PA antigen (3.7 +/- 2.8 micrograms/L) was found as compared with that in the healthy individuals (9.5 +/- 6.0 micrograms/L). Thus, two months after their first incident of symptomatic deep vein thrombosis many of the patients (35%) were found to have decreased fibrinolytic activity. This is the result of highly increased plasma levels of a novel fast inhibitor toward t-PA in combination with a poor ability to release t-PA. Possibly the decreased fibrinolytic activity did play a role in the pathogenesis of deep vein thrombosis in these patients.
对37例近期有症状且经确诊的深静脉血栓形成患者的纤维蛋白溶解系统功能的某些方面进行了研究,并与20名健康人的研究结果进行了比较。采用了新的特异性方法来测量静脉闭塞前后组织型纤溶酶原激活物(t-PA)的活性和抗原,以及最近发现的t-PA快速抑制剂。13例深静脉血栓形成患者(35%)在静脉闭塞后t-PA活性低于0.5 IU/ml,而健康个体中发现的最低活性为0.56 IU/ml。患者总组的t-PA抑制剂水平为3.8±3.7 U/ml(范围0至15.0 U/ml;中位数2.9 U/ml),而健康组为0.7±0.7 U/ml(中位数0.5,范围0至2.4 U/ml)。在闭塞后血浆样本中t-PA活性低的13例患者中,抑制剂水平为6.0±4.4 U/ml。此外,与健康个体(9.5±6.0微克/升)相比,该组患者中t-PA抗原的释放明显较少(3.7±2.8微克/升)。因此,在首次出现症状性深静脉血栓形成两个月后,发现许多患者(35%)的纤维蛋白溶解活性降低。这是一种新型t-PA快速抑制剂血浆水平大幅升高以及t-PA释放能力较差共同作用的结果。纤维蛋白溶解活性降低可能在这些患者深静脉血栓形成的发病机制中起了作用。